Aegis Capital Corp. acted as Exclusive Placement Agent on an $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the Market for Estrella Immunopharma, Inc. (NASDAQ: ES
- Tammer Farid

- 18 hours ago
- 1 min read
1/6/2026 - Aegis Capital Corp. acted as Exclusive Placement Agent on an $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the Market for Estrella Immunopharma, Inc. (NASDAQ: ESLA)
About Estrella Immunopharma, Inc.
Estrella is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Estrella’s mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and other diseases. To accomplish this mission, Estrella’s lead product candidate, EB103, utilizes Eureka’s ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. Estrella is also developing EB104, which also utilizes Eureka’s ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies.

About Aegis Capital Corp.
Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.








Comments